SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending ahead of its Q4 earnings report, with community focus on potential Phase 3 advancement for its oral VK2735 obesity drug, a move expected to accelerate its development. This optimism is reinforced by recent FDA actions against compounded GLP-1s, highlighting the value of VKTX's legitimate and "best-in-class" pipeline in the booming metabolic market.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is actively discussed as its merger with quantum technology company Infleqtion approaches, with a shareholder vote scheduled for February 12 and a ticker change to INFQ expected soon after. The community is bullish, citing Infleqtion's recent NASA and DOE contracts and strong commercial pipeline as reasons it's undervalued compared to its quantum sector peers.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is facing a significant sell-off, reflecting broad market fears that generative AI will disrupt traditional enterprise software and pushing the stock to multi-year lows. Despite widespread panic, a strong contingent of investors highlights the company's robust free cash flow, deep undervaluation, and strategic AI integrations, viewing the current decline as a prime buying opportunity.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following U.S. FDA approval of its Optune Pax for locally advanced pancreatic cancer, hailed by the community as the first new treatment in three decades to extend survival and improve quality of life, which is driving optimism for a significant rally and substantial market penetration.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin Corp ($APP) is trending as a major short-seller retracted false allegations and Reuters corrected an erroneous headline, fueling community calls for a significant rebound and questioning market manipulation amidst strong company fundamentals and high volatility.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is trending after its robust earnings report, showcasing record revenue, gross margin, and its first profitable fiscal year, signaling a significant financial inflection point. The community is actively discussing the strong 'beat and raise' performance and optimistic guidance, emphasizing AI as a growing tailwind for its edge computing and security business.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending after reporting an earnings and revenue beat, driven by accelerating demand for AI infrastructure orders, leading to raised guidance. The community is debating whether this signals a significant AI growth story, potentially pushing the stock towards previous highs, or if it's an overvalued momentum play with ongoing concerns about gross margin pressures from rising memory-chip costs.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following an earnings report that highlighted the operational "Eagle Line" and B-sample shipments to OEMs, with community discussion split between excitement for these production milestones and frustration over the continued absence of specific yield data and named commercial partners.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings (VRT) is surging after reporting strong earnings and an optimistic 2026 outlook, driven by overwhelming demand for its critical power and thermal infrastructure solutions essential for AI data centers. The community is actively discussing VRT's pivotal role in the AI buildout, though some are noting its significant valuation spike.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is trending after reporting strong financial results and forward guidance, along with announcing a $1 billion share repurchase program. The community is actively debating whether these positive fundamentals and a potential short squeeze can counter prevailing fears of AI disruption and challenges to the company's growth levers within the broader software sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Q4 Earnings Call Highlights

Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year...

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results, Beats Expectations By $0.99 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating analysts...

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire WASHINGTON, Feb. 11...

Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +1.91% and +4.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 23.3% in January

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, MarketBeat.com reports...

$VNDA Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$2.39 down -2887.50% YoY
• Vanda Pharmaceuticals Inc. expects 2026 total revenues to be between $230M and $260M, with Fanapt net product sales projected at $150M to $170M, and other net product sales at $80M to $90M.

Stocktwits

Vanda Pharmaceuticals Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$2.39 down -2887.50% YoY
• Vanda Pharmaceuticals Inc. expects 2026 total revenues to be between $230M and $260M, with Fanapt net product sales projected at $150M to $170M, and other net product sales at $80M to $90M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

Coinbase Global Inc

Stocktwits Polls

Many traders are eyeing a potential short squeeze, citing over 50% short interest on a tight public float of 2.9 million shares, hinting at algorithmic manipulation.

Significant excitement surrounds the upcoming Phase 3 trial for Tradipitant, which aims to prevent GLP-1 analogue induced vomiting, with many seeing it as a 'mega blockbuster potential market'.

Anticipation is building for the FDA's February 21st PDUFA decision regarding Bysanti, with many investors front-running the potential approval catalyst.

Traders are actively speculating on significant upward price movements, with various targets ranging from $8.50 to $15 per share after expected catalysts and new product approvals.

Discussions focus on the recently reported Q4 GAAP EPS of -$2.39 and the 2026 revenue guidance between $230M and $260M, as investors evaluate current financials and future outlook.

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest VNDA News

VNDAVanda Pharmaceuticals Inc